SELLAS Life Sciences Group, Inc. operates as a biopharmaceutical company. The Company develops late-stage oncology drugs and therapies for the treatment of cancer diseases. SELLAS Life Sciences Group serves patients worldwide.

Current Report (Form 8-K | Period ending 2025-01-23)

Current Report (Form 8-K | Period ending 2025-01-10)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SELLAS Life Sciences Group (SLS US)

Current Report (Form 8-K | Period ending 2025-01-23)

Current Report (Form 8-K | Period ending 2025-01-10)

Current Report (Form 8-K | Period ending 2024-12-10)

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)